Table 1.

Harms, benefits, and ICER for the efficient screening strategies. Results per 1000 men invited

Screening age	Number of tests	Screening interval	PCM reduction %	Overdiagnosis, as % of screen‐detected men	ICER in € Per QALY
56 single test	1	‐	6.9	29.3	10 211
57 single test	1	‐	8.2	30.7	10 946
55‐58	2	3	12.2	31.4	12 814
55‐59	2	4	13.8	31.6	13 129
55‐61	3	3	19.8	34.6	14 738
54‐63	4	3	25.1	34.7	18 417
55‐64	4	3	27.2	35.8	19 733
54‐64	6	2	30	34.9	22 395
55‐65	6	2	32.2	36	24 589
53‐65	7	2	33	35.6	24 819
54‐66	7	2	35	36.7	28 053
53‐67	8	2	37.6	37.4	29 565
52‐68	9	2	39	38.1	36 805
50‐68	10	2	40.3	37.9	43 831
51‐69	10	2	42	38.9	50 572
53‐69	17	1	46	38	55 083
52‐69	18	1	46.4	37.9	57 448
50‐69	20	1	46.9	41.3	97 784

Abbreviations: ICER, incremental cost‐effectiveness ratio; PCM, prostate cancer mortality; QALY, quality‐adjusted life years.